Report

Global veterinary CRO market is projected to witness a CAGR of 7.07% during the forecast period 2025-2032, growing from USD 745.37 million in 2024 to USD 1,287.08 million in 2032. The veterinary contract research organization (CRO) market is growing progressively due to increasing demand for outsourced R&D services within the animal health sector. Major drivers of this growth include a rise in companion animal numbers, increased pet healthcare expenditures, and the growing complexity of veterinary drug development. Firms are contracting preclinical and clinical research with CROs as a way of saving on costs, ensuring compliance with regulations, and accelerating their products' launches.
In addition to that, the market is driven by technology, which has an impact, such as AI-directed diagnostics, wearable health monitors, and cloud-based data platforms that support higher attainment and accuracy in trials. The rise of the biologics and personalized medicines sector also continues to push growth by requiring service expertise from CROs. North America continues to lead the market, supported by a favorable pet care ecosystem and pre-established CRO infrastructure.
For instance, in May 2025, Mars, Incorporated launched an AI-powered tool for pet dental checks, enabling early detection of oral health issues in companion animals through innovative imaging and data analysis.
Technological Innovations Drive Growth in the Veterinary CRO Market
Technological innovations play a crucial role in the veterinary CRO segment. Innovations in AI-powered data analytics, digital pathology, computerized trial monitoring, and in silico simulations enable faster, precise, and agile preclinical and clinical research. These technologies help CROs develop models of drug response, optimize doses, and identify early warning signs of safety, thereby reducing reliance on animal models and enriching the results of finished trials. In addition, wearable animal health devices and real-time health monitoring have transformed data capture during field trials, particularly with companion animals. Cloud systems enable enhanced global collaboration between regulators, CROs, and sponsors, allowing for improved clarity and worldwide real-time accessibility of data. Also, innovations in biologics manufacturing, formulation science, and advanced imaging enable the development of increasingly sophisticated and targeted veterinary therapeutics. These innovations not only strengthen the R&D capability of a CRO itself but also empower animal health companies to cope with increased regulations and gain time-to-market.
For instance, in June 2025, Boehringer Ingelheim International GmbH and Eko Health Inc. entered a digital health partnership with the aim of enhancing heart murmur detection in dogs. The agreement signifies rising engagement of digital developments across animal health and supports broadening applications of smart diagnostic devices across research and development projects with assistance from CROs.
Increasing Demand for Integrated and Specialized Veterinary CRO Services
Increased demand for combined and specialist veterinary CRO services is a key driving force reshaping the veterinary CRO sector. As advanced drug development in the veterinary domain is fueled by innovative advances in biologics, combination products, and prevention drugs, animal health companies need their CRO counterparts to offer seamless, broad-spectrum research and development services. From early-stage discovery and preclinical research through clinical trials to regulatory approval and manufacturing services, this one-stop approach optimizes time-to-market while improving data consistency, regulatory compliance, and cost efficiency. There is also growing demand within the sector for specialist CROs with a core competence in areas like parasiticides, dermatology, and chronic care products for companion animals.
For instance, in January 2025, Argenta Holdco Limited, a leading animal health pharmaceutical services company, announced a strategic realignment of its CRO platform, effective immediately. This move aims to enhance the efficiency, specialization, and global coordination of its contract research operations, reflecting the growing demand for streamlined and integrated CRO services in response to rising R&D complexity and outsourcing trends in the animal health industry.
Companion Animals, a Dominant Segment in Veterinary CRO Market
The companion animal segment is at the forefront of the veterinary CRO market due to worldwide growth in pet ownership and the humanization of pets globally. Pet owners these days take an active interest in animal health, and consequently, they need sophisticated veterinary care, preventive therapy, and advanced medications. This has led animal health companies to increase their research and development (R&D) spending on companion animal medicines manifold, particularly in mature markets such as North America and Europe. Veterinary CROs are also observing an increase in outsourcing of services, including drug development, phase I-IV clinical research, and regulatory services specifically tailored for dogs and cats.
Further, increased numbers of chronic disease cases such as obesity, arthritis, diabetes, and parasitic infections among companion animals have also boosted demands for continuous drug innovations. CROs have helped firms shorten the time-to-market of companion animal drugs and achieve compliance with ever-changing regulations.
For instance, in October 2024, Elanco Animal Health Incorporated received FDA approval for Credelio Quattro. This chewable tablet combines lotilaner, moxidectin, praziquantel, and pyrantel, offering the broadest protection against canine oral parasiticides in a single monthly dose. This highlights continued innovation in companion animal therapeutics and the role of CROs in supporting complex product development and regulatory success.
North America Dominates the Global Market Size
North America is a leading player in the global veterinary CRO market, led by a combination of strategic and structural strengths. The region boasts a highly advanced veterinary healthcare infrastructure and a mature ecosystem of drug and biopharmaceutical players, which are heavily committed to research in animal health. The United States stands as a leader in this area due to its high spending on veterinary medicine, a large pet population, and expanding knowledge of zoonotic diseases. Efficient regulatory support from organizations like the U.S. FDA's Center for Veterinary Medicine (CVM) enables streamlined drug clearance processes, fosters research innovations, and shortens research schedules.
In addition, North America also hosts many preeminent veterinary CROs like Charles River Laboratories International, Inc., Inotiv, Inc., and Clinvet USA LLC, which provide a broad scope of services ranging from preclinical research to advisory services on regulations. These CROs have established long-term relationships with global pharmaceutical companies and academic centers, solidifying the region's position as a research hub for veterinary research. The increasing trend of outsourcing in animal health, driven by rising R&D expenditures and a demand for specialized expertise, has also spurred rapid growth.
The area also has a highly trained employee pool, state-of-the-art research centers, and an attractive environment for biotech and animal health entrepreneurial ventures.
For instance, in October 2024, Argenta Holdco Limited announced the acquisition of a sterile fill-finish manufacturing site in Shawnee, Kansas, dedicated exclusively to the animal health industry. This move strengthens Argenta's United States operations and expands its capabilities in manufacturing services for veterinary pharmaceuticals.
Impact of U.S. Tariffs on Global Veterinary CRO market
- Increased Operational Costs
Customs duties on lab equipment as well as animal health products raise the costs of CROs, which reduces their profitability.
- Supply Chain Disruptions
Delays or rerouting due to tariffs on materials from China or other countries disrupt timely research services.
- Decreased Interconnectedness
International customers can opt for non-U.S.-based CROs due to concerns over tariff-driven increases driving prices, decreasing firms' competitiveness.
- Change in Outsourcing Strategy
Companies may move operations or partnerships to countries with favorable trade terms, altering demand for U.S. veterinary CROs.
- Regulatory Uncertainty
Frequent shifts in tariff policy pose planning hurdles for CROs making long-term investments.
Key Players Landscape and Outlook
The global veterinary CRO market is expanding as key players adopt innovative strategies to cater to shifting needs of the animal health segment. Leaders such as Charles River Laboratories International, Inc., Inotiv, Inc., Argenta Holdco Limited, Clinvet SD (of Clinglobal), and KLIFOVET GmbH dominate, with advanced technology, expanding geographical presence, and building broader services across the lifecycle of R&D. Competitors aren't just investing in preclinical and clinical trial services, regulated services, non-animal testing alternatives, and biologics as well. Pressure on ethical research methods, rapid development cycles, and compliance with global regulations is causing competitors to shift toward efficient and humane practices. Merger and acquisition, public-private partnerships, and partnerships have become commonplace among worldwide CROs, which are looking to build their client base as much as develop their technical expertise.
Further emphasis on sustainability, data-driven discovery, and digital integration, such as AI-powered trial tracking and virtual simulations, is transforming competition within the veterinary CRO segment. These facilitate organizations in streamlining processes, reducing costs, and achieving a quicker time-to-market for veterinary drugs and biologics. Overall, the scenario is favorable, with increasing pet health expenditures, concerns about zoonotic diseases, and advancements in veterinary therapeutics.
For instance, in June 2024, Charles River Laboratories International, Inc., in collaboration with MatTek Corporation, awarded a grant from the Foundation for Chemistry Research and Initiatives to advance non-animal research alternatives, demonstrating the industry's growing commitment to innovative, ethical, and sustainable approaches in veterinary research.